Woods DR, Pollard AJ, Collier DJ, Jamshidi Y, Vassiliou V, Hawe E, Humphries SE, Montgomery HE. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and arterial oxygen saturation at high altitude. Am J Respir Crit Care Med. 2002;166(3):362-6.
Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost-effectiveness of zanamivir for the treatment of influenza in a high-risk population in Australia. Pharmacoeconomics. 2000 Jun;17(6):611-20. doi: 10.2165/00019053-200017060-00007.
Sculpher M, Palmer MK, Heyes AE. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000 Apr;17(4):361-70.
Shapiro G, Lumry W, Wolfe J, Given J, White MV, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):527-34. doi: 10.1164/ajrccm.161.2.9905091
McKenna SP, Doward LC. A review of quality of life in Alzheimer's disease. Parts 1 and 2: issues in assessing disease impact and drug effects. Pharmacoeconomics. 1999 Oct;16(4):417-9.
Whalley D, McKenna SP. Measuring quality of life in patients with depression or anxiety. Pharmacoeconomics. 1995 Oct;8(4):305-15.
McKenna SP, Doward LC. Quality-of-life assessment of adults with growth hormone deficiency: implications for drug therapy. Pharmacoeconomics. 1994 Nov 1;6(5):434-41.